Small Vessel Disease Explains Reduced Thrombectomy Benefit in Older Patients

Brain Frailty and the Limits of Reperfusion

Endovascular thrombectomy is the established standard of care for acute ischemic stroke from large vessel occlusions in the anterior circulation [1, 2, 3]. While trials like DAWN have expanded the therapeutic window to 24 hours, outcomes remain variable, with a 49% functional independence rate in the thrombectomy group versus 13% in controls [4, 5]. Current guidelines prioritize rapid reperfusion to salvage the ischemic penumbra, the at-risk tissue surrounding the infarct, as the probability of a favorable outcome declines with each passing hour [6, 7]. However, chronological age, often associated with poorer recovery, may be an imprecise proxy for the brain's underlying physiological resilience [8]. A new analysis of data from the RESILIENT trial investigates whether specific markers of baseline neurovascular health on imaging provide more definitive prognostic value than age alone.

Quantifying Neurovascular Reserve in the RESILIENT Cohort

The analysis drew from the RESILIENT trial, a multicenter, prospective, randomized study conducted in Brazil. The trial enrolled patients with anterior circulation large-vessel occlusion stroke, a condition with a high risk of severe disability, and randomized them to either mechanical thrombectomy plus guideline-based care or guideline-based care alone. Guideline-based care included intravenous alteplase for eligible patients in both arms. To ensure objectivity, patient outcomes were evaluated by clinicians who were blinded to the treatment assignments. The primary endpoint was a good functional outcome, defined as a modified Rankin Scale (mRS) score of 0 to 2 at 90 days. This range on the mRS signifies functional independence, from no symptoms to a slight disability that does not interfere with activities of daily living.

CT Markers as Proxies for Brain Frailty

This secondary analysis aimed to determine if baseline computed tomography (CT) markers of cerebral small vessel disease (cSVD) could explain the observed association between advancing age and poorer functional outcomes. A vascular neurologist, blinded to all clinical data, evaluated baseline CT scans for three key indicators of chronic cerebrovascular injury: leukoaraiosis (white matter hypodensities), lacunes (small, deep infarcts), and brain atrophy. These markers were combined to create a composite cSVD score, which served as a surrogate for brain frailty. This concept of frailty reflects a state of reduced physiological reserve, where the brain's microvasculature is already compromised, potentially limiting its ability to recover from an acute ischemic event. The researchers then assessed treatment effects across subgroups defined by age (less than 70 versus 70 or older) and by the cSVD burden, which was categorized as low (score of 0 to 1) or high (2 to 3). This design allowed the investigators to test whether the diminished benefit of thrombectomy in older patients is driven by age itself or by the underlying neurovascular damage quantified by the cSVD score.

Predictors of Functional Independence

In the RESILIENT cohort, patients who achieved functional independence at 90 days shared a distinct baseline profile. They were typically younger, presented with lower National Institutes of Health Stroke Scale (NIHSS) scores, had better collateral circulation to the ischemic territory, and exhibited lower baseline glucose levels. Critically, these patients also had a lower burden of cerebral small vessel disease and were more frequently treated with mechanical thrombectomy. A subsequent multivariable logistic regression analysis confirmed which of these factors were independent predictors of a good outcome. The analysis isolated lower NIHSS scores, treatment with mechanical thrombectomy, lower baseline glucose, and a lower composite cSVD score as statistically significant variables. The finding that baseline CT markers of cSVD were independently associated with poorer outcomes is particularly noteworthy, as it suggests that pre-existing chronic vascular damage imposes a significant ceiling on recovery potential, even when reperfusion of the large vessel is successful.

The Mediating Role of Small Vessel Disease

The analysis revealed that the clinical benefit of mechanical thrombectomy was contingent on both age and the baseline integrity of the cerebral microvasculature. A significant treatment effect was observed, but it was restricted to patients younger than 70 years who also had a low burden of cerebral small vessel disease (composite score 0 to 1). Within this specific subgroup, thrombectomy was associated with a substantial increase in the odds of achieving functional independence (odds ratio [OR] = 4.16, 95% confidence interval [CI] = 1.6 to 10.4, p < 0.01). In contrast, no benefit from mechanical thrombectomy was observed in patients aged 70 or older, nor in any patient with a cSVD score greater than 1, regardless of age. To clarify the interplay between these factors, the authors performed a mediation analysis, a statistical technique used to determine if a third variable explains the relationship between an exposure and an outcome. The analysis showed that cSVD significantly mediated the association between age and functional outcome (average causal mediation effect [ACME] = –0.003, 95% CI = –0.005 to 0.00, p = 0.010). This result provides statistical evidence that the chronic vascular damage captured by the cSVD score, rather than age itself, may explain the lack of thrombectomy efficacy in many older patients. For clinicians, these findings suggest that a simple evaluation of cSVD markers on a baseline non-contrast CT could offer a more precise prognostic tool than age for identifying patients most likely to benefit from reperfusion therapy.

References

1. Berkhemer OA, Fransen P, Beumer D, et al. A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke. New England Journal of Medicine. 2014. doi:10.1056/nejmoa1411587

2. Goyal M, Demchuk AM, Menon BK, et al. Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke. New England Journal of Medicine. 2015. doi:10.1056/nejmoa1414905

3. Saver JL, Goyal M, Bonafé A, et al. Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke. New England Journal of Medicine. 2015. doi:10.1056/nejmoa1415061

4. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. New England Journal of Medicine. 2018. doi:10.1056/nejmoa1713973

5. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. New England Journal of Medicine. 2017. doi:10.1056/nejmoa1706442

6. Jauch EC, Saver JL, Adams HP, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2013. doi:10.1161/str.0b013e318284056a

7. Saver JL, Goyal M, Lugt AVD, et al. Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis. JAMA. 2016. doi:10.1001/jama.2016.13647

8. Zheng W, Tang Y, Lin H, et al. Atrial Fibrillation and Clinical Outcomes of Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-Analysis of Adjusted Effect Estimates.. Journal of the American Heart Association. 2023. doi:10.1161/JAHA.123.031733